Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Liu, Yunpeng"" wg kryterium: Autor


Tytuł :
TGFB2 serves as a link between epithelial-mesenchymal transition and tumor mutation burden in gastric cancer.
Autorzy :
Yang B; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang 110001, China; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang 110001, China; Liaoning Province Clinical Research Center for Cancer, Shenyang 110001, China; Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, Shenyang 110001, China.
Bai J; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang 110001, China; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang 110001, China; Liaoning Province Clinical Research Center for Cancer, Shenyang 110001, China; Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, Shenyang 110001, China.
Shi R; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang 110001, China; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang 110001, China; Liaoning Province Clinical Research Center for Cancer, Shenyang 110001, China; Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, Shenyang 110001, China.
Shao X; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang 110001, China; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang 110001, China; Liaoning Province Clinical Research Center for Cancer, Shenyang 110001, China; Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, Shenyang 110001, China.
Yang Y; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang 110001, China; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang 110001, China; Liaoning Province Clinical Research Center for Cancer, Shenyang 110001, China; Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, Shenyang 110001, China.
Jin Y; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang 110001, China; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang 110001, China; Liaoning Province Clinical Research Center for Cancer, Shenyang 110001, China; Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, Shenyang 110001, China.
Che X; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang 110001, China; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang 110001, China; Liaoning Province Clinical Research Center for Cancer, Shenyang 110001, China; Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, Shenyang 110001, China.
Zhang Y; Laboratory I of Cancer Institute, the First Hospital of China Medical University, Shenyang 110001, China.
Qu X; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang 110001, China; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang 110001, China; Liaoning Province Clinical Research Center for Cancer, Shenyang 110001, China; Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, Shenyang 110001, China.
Liu Y; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang 110001, China; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang 110001, China; Liaoning Province Clinical Research Center for Cancer, Shenyang 110001, China; Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, Shenyang 110001, China. Electronic address: .
Li Z; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang 110001, China; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang 110001, China; Liaoning Province Clinical Research Center for Cancer, Shenyang 110001, China; Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, Shenyang 110001, China. Electronic address: .
Pokaż więcej
Źródło :
International immunopharmacology [Int Immunopharmacol] 2020 Jul; Vol. 84, pp. 106532. Date of Electronic Publication: 2020 May 06.
Typ publikacji :
Journal Article
MeSH Terms :
Epithelial-Mesenchymal Transition*
Mutation*
Biomarkers, Tumor/*immunology
Stomach Neoplasms/*immunology
Transforming Growth Factor beta2/*immunology
Aged ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; Male ; Prognosis ; Stomach Neoplasms/genetics ; Stomach Neoplasms/mortality
Czasopismo naukowe
Tytuł :
β-Elemene inhibits the metastasis of multidrug-resistant gastric cancer cells through miR-1323/Cbl-b/EGFR pathway.
Autorzy :
Deng M; Department of Respiratory and Infectious Disease of Geriatrics, the First Hospital of China Medical University, Shenyang 110001, China; Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing 100029, China; Graduate School of Peking Union Medical College, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100005, China.
Liu B; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang 110001, China; Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou 310000, Zhejiang, China.
Song H; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang 110001, China.
Yu R; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang 110001, China.
Zou D; The First Laboratory of Cancer Institute, The First Hospital of China Medical University, Shenyang 110001, China.
Chen Y; Department of Respiratory and Infectious Disease of Geriatrics, the First Hospital of China Medical University, Shenyang 110001, China.
Ma Y; Department of Medical Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang 110042, China.
Lv F; The First Laboratory of Cancer Institute, The First Hospital of China Medical University, Shenyang 110001, China.
Xu L; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang 110001, China.
Zhang Z; Department of Pathology, Shengjing Hospital of China Medical University, Shenyang 110001, China.
Lv Q; Department of Pathology, Shengjing Hospital of China Medical University, Shenyang 110001, China.
Yang X; Department of Pathology, Shengjing Hospital of China Medical University, Shenyang 110001, China.
Che X; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang 110001, China.
Qu X; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang 110001, China.
Liu Y; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang 110001, China.
Zhang Y; The First Laboratory of Cancer Institute, The First Hospital of China Medical University, Shenyang 110001, China. Electronic address: .
Hu X; Department of Respiratory and Infectious Disease of Geriatrics, the First Hospital of China Medical University, Shenyang 110001, China. Electronic address: .
Pokaż więcej
Źródło :
Phytomedicine : international journal of phytotherapy and phytopharmacology [Phytomedicine] 2020 Apr; Vol. 69, pp. 153184. Date of Electronic Publication: 2020 Feb 10.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents, Phytogenic/*pharmacology
Drug Resistance, Neoplasm/*drug effects
Sesquiterpenes/*pharmacology
Stomach Neoplasms/*drug therapy
Stomach Neoplasms/*pathology
Adaptor Proteins, Signal Transducing/genetics ; Adaptor Proteins, Signal Transducing/metabolism ; Animals ; Cell Line, Tumor ; Drug Resistance, Neoplasm/genetics ; Epithelial-Mesenchymal Transition/drug effects ; ErbB Receptors/genetics ; ErbB Receptors/metabolism ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/secondary ; Male ; Matrix Metalloproteinases/genetics ; Matrix Metalloproteinases/metabolism ; Mice, Nude ; MicroRNAs/genetics ; Proto-Oncogene Proteins c-cbl/genetics ; Proto-Oncogene Proteins c-cbl/metabolism ; Signal Transduction/drug effects ; Stomach Neoplasms/genetics
Czasopismo naukowe
Tytuł :
TNPO2 operates downstream of DYNC1I1 and promotes gastric cancer cell proliferation and inhibits apoptosis.
Autorzy :
Gong L; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Wen T; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Li Z; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Wang Y; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Wang J; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Che X; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Liu Y; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Qu X; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Pokaż więcej
Źródło :
Cancer medicine [Cancer Med] 2019 Dec; Vol. 8 (17), pp. 7299-7312. Date of Electronic Publication: 2019 Oct 11.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Cell Nucleus/*metabolism
Cytoplasmic Dyneins/*metabolism
Stomach Neoplasms/*pathology
beta Karyopherins/*metabolism
Acetylation ; Active Transport, Cell Nucleus ; Apoptosis/genetics ; Cell Line, Tumor ; Cell Proliferation/genetics ; Cyclin-Dependent Kinase Inhibitor p21/metabolism ; E1A-Associated p300 Protein ; Gene Expression Profiling ; Gene Expression Regulation, Neoplastic ; Histones/metabolism ; Humans ; Promoter Regions, Genetic/genetics ; Sp1 Transcription Factor/metabolism ; Up-Regulation ; beta Karyopherins/genetics
Czasopismo naukowe
Tytuł :
ASO Author Reflections: The Prognostic Role of Exosomal PD-L1 in Patients with Gastric Cancer.
Autorzy :
Fan Y; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Liu Y; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China. .; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China. .
Qu X; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Pokaż więcej
Źródło :
Annals of surgical oncology [Ann Surg Oncol] 2019 Dec; Vol. 26 (Suppl 3), pp. 851-852. Date of Electronic Publication: 2019 Nov 18.
Typ publikacji :
Journal Article
MeSH Terms :
B7-H1 Antigen/*metabolism
Biomarkers, Tumor/*metabolism
Exosomes/*metabolism
Stomach Neoplasms/*mortality
Humans ; Prognosis ; Stomach Neoplasms/immunology ; Stomach Neoplasms/metabolism ; Stomach Neoplasms/pathology ; Survival Rate
Czasopismo naukowe
Tytuł :
Exosomal PD-L1 Retains Immunosuppressive Activity and is Associated with Gastric Cancer Prognosis.
Autorzy :
Fan Y; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Che X; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Qu J; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Hou K; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Wen T; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Li Z; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Li C; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Wang S; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Xu L; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Liu Y; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China. .; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China. .
Qu X; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China. .; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China. .
Pokaż więcej
Źródło :
Annals of surgical oncology [Ann Surg Oncol] 2019 Oct; Vol. 26 (11), pp. 3745-3755. Date of Electronic Publication: 2019 May 13.
Typ publikacji :
Journal Article
MeSH Terms :
Immunosuppression*
Adenocarcinoma/*secondary
B7-H1 Antigen/*blood
B7-H1 Antigen/*immunology
Exosomes/*metabolism
Stomach Neoplasms/*pathology
Adenocarcinoma/blood ; Adenocarcinoma/immunology ; Adenocarcinoma/surgery ; Adult ; Aged ; Aged, 80 and over ; Biomarkers, Tumor/blood ; Biomarkers, Tumor/immunology ; Female ; Follow-Up Studies ; Humans ; Lymphatic Metastasis ; Male ; Middle Aged ; Prognosis ; Retrospective Studies ; Stomach Neoplasms/blood ; Stomach Neoplasms/immunology ; Stomach Neoplasms/surgery ; Survival Rate
Czasopismo naukowe
Tytuł :
β-Elemene inhibits peritoneal metastasis of gastric cancer cells by modulating FAK/Claudin-1 signaling.
Autorzy :
Deng M; Department of Respiratory and Infectious Disease of Geriatrics, The First Hospital of China Medical University, Shenyang, China.
Zhang Y; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Liu B; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Chen Y; Department of Respiratory and Infectious Disease of Geriatrics, The First Hospital of China Medical University, Shenyang, China.
Song H; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Yu R; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Che X; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Qu X; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Liu Y; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Hu X; Department of Respiratory and Infectious Disease of Geriatrics, The First Hospital of China Medical University, Shenyang, China.
Xu X; Department of Gastroenterology, The First Hospital of China Medical University, Shenyang, China.
Pokaż więcej
Źródło :
Phytotherapy research : PTR [Phytother Res] 2019 Sep; Vol. 33 (9), pp. 2448-2456. Date of Electronic Publication: 2019 Jul 25.
Typ publikacji :
Journal Article
MeSH Terms :
Claudin-1/*metabolism
Peritoneal Neoplasms/*drug therapy
Sesquiterpenes/*therapeutic use
Stomach Neoplasms/*drug therapy
Animals ; Cell Line, Tumor ; Female ; Humans ; Mice ; Mice, Nude ; Neoplasm Metastasis ; Phosphorylation ; Sesquiterpenes/pharmacology ; Signal Transduction ; Stomach Neoplasms/pathology
Czasopismo naukowe
Tytuł :
Leucine-rich repeat neuronal protein-1 suppresses apoptosis of gastric cancer cells through regulation of Fas/FasL.
Autorzy :
Liu B; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Zhang Y; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Fan Y; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Wang S; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Li Z; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Deng M; Department of Respiratory and Infectious Disease of Geriatrics, The First Hospital of China Medical University, Shenyang, China.
Li C; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Wang J; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Ma R; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Wang X; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Wang Y; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Xu L; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Hou K; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Che X; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Liu Y; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Qu X; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Pokaż więcej
Źródło :
Cancer science [Cancer Sci] 2019 Jul; Vol. 110 (7), pp. 2145-2155. Date of Electronic Publication: 2019 Jun 10.
Typ publikacji :
Journal Article
MeSH Terms :
Signal Transduction*
Up-Regulation*
Membrane Proteins/*genetics
Membrane Proteins/*metabolism
Neoplasm Proteins/*genetics
Neoplasm Proteins/*metabolism
Stomach Neoplasms/*pathology
Animals ; Apoptosis ; Cell Line, Tumor ; Fas Ligand Protein/metabolism ; Female ; Gene Expression Regulation, Neoplastic ; Gene Knockdown Techniques ; Humans ; Male ; Mice ; Neoplasm Transplantation ; Nerve Tissue Proteins ; Prognosis ; Stomach Neoplasms/genetics ; Stomach Neoplasms/metabolism ; Survival Analysis ; Transcription Factor AP-1/metabolism ; fas Receptor/metabolism
Czasopismo naukowe
Tytuł :
MiR-940 promotes the proliferation and migration of gastric cancer cells through up-regulation of programmed death ligand-1 expression.
Autorzy :
Fan Y; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang 110001, China; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang 110001, China.
Che X; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang 110001, China; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang 110001, China.
Hou K; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang 110001, China; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang 110001, China.
Zhang M; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang 110001, China; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang 110001, China.
Wen T; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang 110001, China; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang 110001, China.
Qu X; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang 110001, China; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang 110001, China.
Liu Y; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang 110001, China; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang 110001, China. Electronic address: .
Pokaż więcej
Źródło :
Experimental cell research [Exp Cell Res] 2018 Dec 15; Vol. 373 (1-2), pp. 180-187. Date of Electronic Publication: 2018 Oct 25.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
B7-H1 Antigen/*metabolism
MicroRNAs/*metabolism
Stomach Neoplasms/*genetics
Adaptor Proteins, Signal Transducing/genetics ; Adaptor Proteins, Signal Transducing/metabolism ; Animals ; B7-H1 Antigen/biosynthesis ; B7-H1 Antigen/physiology ; Cell Line, Tumor ; Cell Movement ; Cell Proliferation ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; Jurkat Cells ; Mice, Inbred BALB C ; Mice, Nude ; Proto-Oncogene Proteins c-cbl/genetics ; Proto-Oncogene Proteins c-cbl/metabolism ; STAT5 Transcription Factor/metabolism ; Stomach Neoplasms/metabolism ; Stomach Neoplasms/pathology ; Stomach Neoplasms/physiopathology ; Tumor Suppressor Proteins/metabolism ; Ubiquitination ; Up-Regulation
Czasopismo naukowe
Tytuł :
β-elemene increases the sensitivity of gastric cancer cells to TRAIL by promoting the formation of DISC in lipid rafts.
Autorzy :
Xu L; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, 110001, China.
Guo T; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, 110001, China.
Qu X; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, 110001, China.
Hu X; Department of Respiratory and Infectious Disease of Geriatrics, the First Hospital of China Medical University, Shenyang, 110001, China.
Zhang Y; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, 110001, China.
Che X; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, 110001, China.
Song H; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, 110001, China.
Gong J; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, 110001, China.
Ma R; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, 110001, China.
Li C; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, 110001, China.
Fan Y; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, 110001, China.
Ma Y; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, 110001, China.
Hou K; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, 110001, China.
Wu P; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, 110001, China.
Dong H; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, 110001, China.
Liu Y; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, 110001, China.
Pokaż więcej
Źródło :
Cell biology international [Cell Biol Int] 2018 Sep; Vol. 42 (10), pp. 1377-1385. Date of Electronic Publication: 2018 Jul 23.
Typ publikacji :
Journal Article
MeSH Terms :
Sesquiterpenes/*metabolism
Sesquiterpenes/*pharmacology
Stomach Neoplasms/*metabolism
Antineoplastic Agents/pharmacology ; Apoptosis/drug effects ; Caspase 8/metabolism ; Cell Line, Tumor ; Cell Survival/drug effects ; China ; Death Domain Receptor Signaling Adaptor Proteins/drug effects ; Death Domain Receptor Signaling Adaptor Proteins/metabolism ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Membrane Microdomains ; Signal Transduction/drug effects ; Stomach Neoplasms/pathology ; TNF-Related Apoptosis-Inducing Ligand/drug effects ; TNF-Related Apoptosis-Inducing Ligand/metabolism ; TNF-Related Apoptosis-Inducing Ligand/pharmacology
Czasopismo naukowe
Tytuł :
Caveolin‑1 enhances RANKL‑induced gastric cancer cell migration.
Autorzy :
Wang Y; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.
Song Y; Department of Surgical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.
Che X; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.
Zhang L; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.
Wang Q; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.
Zhang X; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.
Qu J; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.
Li Z; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.
Xu L; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.
Zhang Y; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.
Fan Y; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.
Hou K; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.
Liu Y; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.
Qu X; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.
Pokaż więcej
Źródło :
Oncology reports [Oncol Rep] 2018 Sep; Vol. 40 (3), pp. 1287-1296. Date of Electronic Publication: 2018 Jul 05.
Typ publikacji :
Journal Article
MeSH Terms :
Cell Movement*
Biomarkers, Tumor/*metabolism
Caveolin 1/*metabolism
RANK Ligand/*metabolism
Stomach Neoplasms/*pathology
src-Family Kinases/*metabolism
Apoptosis ; CSK Tyrosine-Protein Kinase ; Cell Proliferation ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Prognosis ; Stomach Neoplasms/metabolism ; Stomach Neoplasms/surgery ; Survival Rate ; Tumor Cells, Cultured
Czasopismo naukowe
Tytuł :
Long non-coding RNA UCA1 upregulation promotes the migration of hypoxia-resistant gastric cancer cells through the miR-7-5p/EGFR axis.
Autorzy :
Yang Z; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Shi X; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Li C; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Wang X; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Hou K; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Li Z; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Zhang X; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Fan Y; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Qu X; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Che X; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China. Electronic address: .
Liu Y; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China. Electronic address: .
Pokaż więcej
Źródło :
Experimental cell research [Exp Cell Res] 2018 Jul 15; Vol. 368 (2), pp. 194-201. Date of Electronic Publication: 2018 May 01.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Cell Hypoxia/*genetics
Cell Movement/*genetics
Drug Resistance, Neoplasm/*genetics
MicroRNAs/*genetics
RNA, Long Noncoding/*genetics
Stomach Neoplasms/*genetics
Up-Regulation/*genetics
3' Untranslated Regions/genetics ; Cell Line, Tumor ; Cell Proliferation/genetics ; ErbB Receptors/genetics ; Gene Expression Regulation, Neoplastic/genetics ; Humans ; RNA, Messenger/genetics ; Transcriptional Activation/genetics ; Tumor Microenvironment/genetics
Czasopismo naukowe
Tytuł :
Cancer-associated fibroblasts-stimulated interleukin-11 promotes metastasis of gastric cancer cells mediated by upregulation of MUC1.
Autorzy :
Wang X; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang 110001, China; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang 110001, China.
Che X; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang 110001, China; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang 110001, China.
Liu C; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang 110001, China; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang 110001, China.
Fan Y; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang 110001, China; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang 110001, China.
Bai M; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang 110001, China; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang 110001, China.
Hou K; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang 110001, China; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang 110001, China.
Shi X; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang 110001, China; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang 110001, China.
Zhang X; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang 110001, China; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang 110001, China.
Liu B; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang 110001, China; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang 110001, China.
Zheng C; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang 110001, China; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang 110001, China.
Liu Y; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang 110001, China; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang 110001, China. Electronic address: .
Qu X; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang 110001, China; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang 110001, China. Electronic address: .
Pokaż więcej
Źródło :
Experimental cell research [Exp Cell Res] 2018 Jul 15; Vol. 368 (2), pp. 184-193. Date of Electronic Publication: 2018 Apr 27.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Cancer-Associated Fibroblasts/*metabolism
Interleukin-11/*metabolism
Mucin-1/*metabolism
Neoplasm Metastasis/*pathology
Stomach Neoplasms/*metabolism
Up-Regulation/*physiology
Animals ; Cancer-Associated Fibroblasts/pathology ; Cell Line, Tumor ; Coculture Techniques/methods ; Female ; Humans ; MAP Kinase Signaling System/physiology ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Neoplasm Invasiveness/pathology ; STAT3 Transcription Factor/metabolism ; Signal Transduction/physiology ; Stomach Neoplasms/pathology ; Transcriptional Activation/physiology ; Tumor Microenvironment/physiology
Czasopismo naukowe
Tytuł :
Chk1 activation attenuates sensitivity of lapatinib in HER2-positive gastric cancer.
Autorzy :
Bai M; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, 110001, China.
Song N; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, 110001, China.
Che X; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, 110001, China.
Wang X; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, 110001, China.
Qu X; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, 110001, China.
Liu Y; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, 110001, China.
Pokaż więcej
Źródło :
Cell biology international [Cell Biol Int] 2018 Jul; Vol. 42 (7), pp. 781-793. Date of Electronic Publication: 2018 May 14.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents/*pharmacology
Checkpoint Kinase 1/*metabolism
Drug Resistance, Neoplasm/*drug effects
Quinazolines/*pharmacology
Receptor, ErbB-2/*metabolism
Stomach Neoplasms/*metabolism
Apoptosis/drug effects ; Cell Line, Tumor ; Cell Proliferation/drug effects ; ErbB Receptors/metabolism ; Humans ; Lapatinib ; Phosphorylation
Czasopismo naukowe
Tytuł :
miR-200a enhances TRAIL-induced apoptosis in gastric cancer cells by targeting A20.
Autorzy :
Guo T; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, 110001, China.
Zhang Y; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, 110001, China.
Qu X; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, 110001, China.
Che X; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, 110001, China.
Li C; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, 110001, China.
Fan Y; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, 110001, China.
Wan X; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, 110001, China.
Ma R; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, 110001, China.
Hou K; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, 110001, China.
Zhou H; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, 110001, China.
He X; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, 110001, China.
Hu X; Department of Respiratory Medicine, the First Hospital of China Medical University, Shenyang, 110001, China.
Liu Y; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, 110001, China.
Xu L; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, 110001, China.
Pokaż więcej
Źródło :
Cell biology international [Cell Biol Int] 2018 May; Vol. 42 (5), pp. 506-514. Date of Electronic Publication: 2018 Jan 25.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents/*pharmacology
MicroRNAs/*metabolism
Stomach Neoplasms/*metabolism
TNF-Related Apoptosis-Inducing Ligand/*pharmacology
Tumor Necrosis Factor alpha-Induced Protein 3/*metabolism
Apoptosis ; Caspase 8/metabolism ; Cell Line, Tumor ; Gene Expression Regulation, Neoplastic ; Humans ; Receptor-Interacting Protein Serine-Threonine Kinases/metabolism ; Stomach Neoplasms/genetics ; Tumor Necrosis Factor alpha-Induced Protein 3/genetics ; Ubiquitination
Czasopismo naukowe
Tytuł :
CXCL9/10/11, a regulator of PD-L1 expression in gastric cancer.
Autorzy :
Zhang C; Department of Medical Oncology, the First Hospital of China Medical University, NO.155, North Nanjing Street, Heping District, Shenyang, 110001, China.; Department of Geratology, the First Hospital of China Medical University, Shenyang, Liaoning Province, China.
Li Z; Department of Medical Oncology, the First Hospital of China Medical University, NO.155, North Nanjing Street, Heping District, Shenyang, 110001, China.
Xu L; Department of Medical Oncology, the First Hospital of China Medical University, NO.155, North Nanjing Street, Heping District, Shenyang, 110001, China.
Che X; Department of Medical Oncology, the First Hospital of China Medical University, NO.155, North Nanjing Street, Heping District, Shenyang, 110001, China.
Wen T; Department of Medical Oncology, the First Hospital of China Medical University, NO.155, North Nanjing Street, Heping District, Shenyang, 110001, China.
Fan Y; Department of Medical Oncology, the First Hospital of China Medical University, NO.155, North Nanjing Street, Heping District, Shenyang, 110001, China.
Li C; Department of Medical Oncology, the First Hospital of China Medical University, NO.155, North Nanjing Street, Heping District, Shenyang, 110001, China.
Wang S; Department of Medical Oncology, the First Hospital of China Medical University, NO.155, North Nanjing Street, Heping District, Shenyang, 110001, China.
Cheng Y; Department of Medical Oncology, the First Hospital of China Medical University, NO.155, North Nanjing Street, Heping District, Shenyang, 110001, China.
Wang X; Department of Medical Oncology, the First Hospital of China Medical University, NO.155, North Nanjing Street, Heping District, Shenyang, 110001, China.
Qu X; Department of Medical Oncology, the First Hospital of China Medical University, NO.155, North Nanjing Street, Heping District, Shenyang, 110001, China. .
Liu Y; Department of Medical Oncology, the First Hospital of China Medical University, NO.155, North Nanjing Street, Heping District, Shenyang, 110001, China. .
Pokaż więcej
Źródło :
BMC cancer [BMC Cancer] 2018 Apr 24; Vol. 18 (1), pp. 462. Date of Electronic Publication: 2018 Apr 24.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Gene Expression Regulation, Neoplastic*
B7-H1 Antigen/*genetics
Chemokines, CXC/*metabolism
Stomach Neoplasms/*genetics
Stomach Neoplasms/*metabolism
B7-H1 Antigen/metabolism ; Biomarkers ; Cell Line, Tumor ; Chemokine CXCL10/metabolism ; Chemokine CXCL11/metabolism ; Chemokine CXCL9/metabolism ; Computational Biology/methods ; Humans ; Immunohistochemistry ; Molecular Sequence Annotation ; Neoplasm Staging ; Phosphatidylinositol 3-Kinases/metabolism ; Proto-Oncogene Proteins c-akt/metabolism ; Receptors, CXCR3/metabolism ; STAT3 Transcription Factor/metabolism ; Signal Transduction ; Stomach Neoplasms/pathology
Czasopismo naukowe
Tytuł :
Src promotes EGF-induced epithelial-to-mesenchymal transition and migration in gastric cancer cells by upregulating ZEB1 and ZEB2 through AKT.
Autorzy :
Zhao L; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning, 110001, P.R. China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, Liaoning, 110001, P.R. China.
Li X; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning, 110001, P.R. China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, Liaoning, 110001, P.R. China.
Song N; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning, 110001, P.R. China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, Liaoning, 110001, P.R. China.
Li A; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning, 110001, P.R. China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, Liaoning, 110001, P.R. China.
Hou K; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning, 110001, P.R. China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, Liaoning, 110001, P.R. China.
Qu X; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning, 110001, P.R. China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, Liaoning, 110001, P.R. China.
Che X; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning, 110001, P.R. China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, Liaoning, 110001, P.R. China.
Liu Y; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning, 110001, P.R. China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, Liaoning, 110001, P.R. China.
Pokaż więcej
Źródło :
Cell biology international [Cell Biol Int] 2018 Mar; Vol. 42 (3), pp. 294-302. Date of Electronic Publication: 2017 Nov 15.
Typ publikacji :
Journal Article
MeSH Terms :
Epidermal Growth Factor/*pharmacology
Proto-Oncogene Proteins c-akt/*metabolism
Stomach Neoplasms/*metabolism
Zinc Finger E-box Binding Homeobox 2/*metabolism
Zinc Finger E-box-Binding Homeobox 1/*metabolism
src-Family Kinases/*metabolism
Cell Line, Tumor ; Cell Movement/drug effects ; Epithelial-Mesenchymal Transition/drug effects ; Humans ; MicroRNAs/metabolism ; Neoplasm Invasiveness ; Recombinant Proteins/pharmacology ; Signal Transduction ; Stomach Neoplasms/genetics ; Stomach Neoplasms/pathology ; Transcriptional Activation ; Up-Regulation
Czasopismo naukowe
Tytuł :
4-Phenybutyric acid promotes gastric cancer cell migration via histone deacetylase inhibition-mediated HER3/HER4 up-regulation.
Autorzy :
Shi X; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, 110001, China.
Zheng C; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, 110001, China.
Li C; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, 110001, China.
Hou K; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, 110001, China.
Wang X; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, 110001, China.
Yang Z; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, 110001, China.
Liu C; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, 110001, China.
Liu Y; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, 110001, China.
Che X; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, 110001, China.
Qu X; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, 110001, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, 110001, China.
Pokaż więcej
Źródło :
Cell biology international [Cell Biol Int] 2018 Jan; Vol. 42 (1), pp. 53-62. Date of Electronic Publication: 2017 Oct 09.
Typ publikacji :
Journal Article
MeSH Terms :
Cell Movement/*drug effects
Histone Deacetylase Inhibitors/*pharmacology
Phenylbutyrates/*pharmacology
Receptor, ErbB-3/*metabolism
Receptor, ErbB-4/*metabolism
Stomach Neoplasms/*metabolism
Stomach Neoplasms/*pathology
Acetylation ; Apoptosis/drug effects ; Cell Line, Tumor ; Histone Acetyltransferases/metabolism ; Histone Deacetylases/metabolism ; Histones/metabolism ; Humans ; MAP Kinase Signaling System/drug effects ; Promoter Regions, Genetic ; Receptor, ErbB-3/genetics ; Receptor, ErbB-4/genetics ; Stomach Neoplasms/enzymology ; Transcriptional Activation ; Up-Regulation/drug effects
Czasopismo naukowe
Tytuł :
Pretreatment platelet-to-lymphocyte ratio is associated with the response to first-line chemotherapy and survival in patients with metastatic gastric cancer.
Autorzy :
Wang J; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Qu J; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Li Z; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Che X; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Liu J; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Teng Y; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Jin B; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Zhao M; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Liu Y; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Qu X; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Pokaż więcej
Źródło :
Journal of clinical laboratory analysis [J Clin Lab Anal] 2018 Jan; Vol. 32 (1). Date of Electronic Publication: 2017 Feb 26.
Typ publikacji :
Journal Article
MeSH Terms :
Stomach Neoplasms*/drug therapy
Stomach Neoplasms*/epidemiology
Stomach Neoplasms*/mortality
Stomach Neoplasms*/pathology
Antineoplastic Agents/*therapeutic use
Blood Platelets/*cytology
Lymphocytes/*cytology
Adult ; Aged ; Female ; Humans ; Kaplan-Meier Estimate ; Liver Neoplasms/drug therapy ; Liver Neoplasms/mortality ; Liver Neoplasms/secondary ; Lung Neoplasms/drug therapy ; Lung Neoplasms/mortality ; Lung Neoplasms/secondary ; Lymphocyte Count ; Male ; Middle Aged ; Platelet Count ; ROC Curve ; Retrospective Studies
Czasopismo naukowe
Tytuł :
DR5-Cbl-b/c-Cbl-TRAF2 complex inhibits TRAIL-induced apoptosis by promoting TRAF2-mediated polyubiquitination of caspase-8 in gastric cancer cells.
Autorzy :
Xu L; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Zhang Y; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Qu X; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Che X; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Guo T; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Li C; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Ma R; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Fan Y; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Ma Y; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Hou K; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Li D; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Hu X; Department of Respiratory Medicine, The First Hospital of China Medical University, Shenyang, China.
Liu B; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Yu R; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Yan H; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Gong J; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Liu Y; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Pokaż więcej
Źródło :
Molecular oncology [Mol Oncol] 2017 Dec; Vol. 11 (12), pp. 1733-1751. Date of Electronic Publication: 2017 Oct 27.
Typ publikacji :
Journal Article
MeSH Terms :
Protein Interaction Maps*
Adaptor Proteins, Signal Transducing/*metabolism
Caspase 8/*metabolism
Proto-Oncogene Proteins c-cbl/*metabolism
Receptors, TNF-Related Apoptosis-Inducing Ligand/*metabolism
Stomach Neoplasms/*metabolism
TNF Receptor-Associated Factor 2/*metabolism
TNF-Related Apoptosis-Inducing Ligand/*metabolism
Apoptosis ; Cell Line, Tumor ; Humans ; Ubiquitination
Czasopismo naukowe
Tytuł :
A Four-Factor Immunoscore System That Predicts Clinical Outcome for Stage II/III Gastric Cancer.
Autorzy :
Wen T; Department of Medical Oncology, Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Heping District, Shenyang, China.
Wang Z; Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, Heping District, Shenyang, China.
Li Y; Department of Pathology, Cancer Hospital of Liaoning Province, Dadong District, Shenyang, China.
Li Z; Department of Medical Oncology, Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Heping District, Shenyang, China.
Che X; Department of Medical Oncology, Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Heping District, Shenyang, China.
Fan Y; Department of Medical Oncology, Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Heping District, Shenyang, China.
Wang S; Department of Medical Oncology, Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Heping District, Shenyang, China.
Qu J; Department of Medical Oncology, Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Heping District, Shenyang, China.
Yang X; Department of Pathology, Shengjing Hospital of China Medical University, Heping District, Shenyang, China.
Hou K; Department of Medical Oncology, Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Heping District, Shenyang, China.
Zhou W; Department of Pathology, Shengjing Hospital of China Medical University, Heping District, Shenyang, China.
Xu L; Department of Medical Oncology, Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Heping District, Shenyang, China.
Li C; Department of Medical Oncology, Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Heping District, Shenyang, China.
Wang J; Department of Medical Oncology, Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Heping District, Shenyang, China.
Liu J; Department of Medical Oncology, Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Heping District, Shenyang, China.
Chen L; Department of Pathology, Cancer Hospital of Liaoning Province, Dadong District, Shenyang, China.
Zhang J; Department of Medical Oncology, Cancer Hospital of Liaoning Province, Dadong District, Shenyang, China.
Qu X; The First Hospital of China Medical University, No. 155, Nanjing North Street, Heping District, Shenyang 110001, China. .
Liu Y; The First Hospital of China Medical University, No. 155, Nanjing North Street, Heping District, Shenyang 110001, China. .
Pokaż więcej
Źródło :
Cancer immunology research [Cancer Immunol Res] 2017 Jul; Vol. 5 (7), pp. 524-534. Date of Electronic Publication: 2017 Jun 15.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Prognosis*
Biomarkers, Tumor/*immunology
Stomach Neoplasms/*immunology
Adult ; Aged ; B7-H1 Antigen/immunology ; CD8-Positive T-Lymphocytes/immunology ; Female ; Humans ; Kaplan-Meier Estimate ; Lymphatic Metastasis/immunology ; Male ; Middle Aged ; Neoplasm Staging ; Programmed Cell Death 1 Receptor/immunology ; Proportional Hazards Models ; Stomach Neoplasms/diagnosis ; Stomach Neoplasms/pathology
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies